|
Cost-effectiveness analysis of the national decentralization
policy of antiretroviral treatment programme in Zambia.
Miyano S, Syakantu G, Komada K, Endo H, Sugishita T.
Cost Eff Resour Alloc.
2017 Apr 12;15:4.
Abstract
Antiretroviral Treatment Switching and Its Association With Economic
Outcomes and Adverse Treatment Effects Among Commercially Insured and
Medicaid-Enrolled Patients With HIV in the United States.
Korsnes JS, Goodwin BB, Murray M, Candrilli SD.
Ann Pharmacother.
2016 Jul 20.
Abstract
Cost considerations in the current ARV era.
Eaton EF,
Tamhane A, Saag M,
AIDS.
2016 Apr 14.
Abstract
FULL-TEXT ARTICLE
Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for
Treatment of HIV-1 Infection in the United States.
Sweet D, L Altice F, J Cohen C, Vandewalle B.
PLoS One. 2016 Jan
25;11(1):e0147821.
Paper
Hidden costs of antiretroviral treatment: the public health efficiency of drug
packaging. [Spain]
Andreu-Crespo Ŕ, Llibre JM,
Drug Des Devel Ther. 2015 Aug
5;9:4287-90.
Abstract
Cost-effectiveness analysis of antiretroviral therapy in a cohort of
HIV-infected patients starting first-line highly active antiretroviral therapy
during 6 years of observation.
Maggiolo F, Colombo GL, Di Matteo S,
et al
Patient Relat Outcome Meas. 2015 Feb 17;6:53-6
Abstract
Predicting time to threshold for initiating antiretroviral
treatment to evaluate cost of treatment as HIV prevention.
Lynch ML, DeGruttola V.
J R Stat Soc Ser C Appl Stat.
2015 Feb 1;64(2):359-375.
Abstract
Cost of HAART in Italy: multicentric evaluation and determinants
from a large HIV outpatient cohort.
Tontodonati M, Cenderello G, Celesia BM, et al
Clinicoecon Outcomes Res. 2014 Dec 22;7:27-35
Abstract
Prices paid for adult and paediatric antiretroviral treatment by
low- and middle-income countries in 2012: high, low or just right?
Perriëns JH, Habiyambere V, Dongmo-Nguimfack B, Hirnschall G.
Antivir Ther. 2014;19(Suppl 3):39-47.
Abstract
Intellectual property rights, market competition and access to
affordable antiretrovirals.
Pascual F.
Antivir Ther. 2014;19(Suppl 3):57-67
Abstract
Scaling-up the use of generic antiretrovirals in resource-limited
countries: generic drugs for health.
Beck EJ, Passarelli C, Lui I, et al
Antivir Ther. 2014;19(Suppl 3):117-123.
Abstract
FULL-TEXT ARTICLE
Taking ART to Scale: Determinants of the Cost and Cost-Effectiveness of
Antiretroviral Therapy in 45 Clinical Sites in Zambia.
Marseille E, Giganti MJ, Mwango A, et al
PLoS One. 2012;7(12):e51993.
Paper |
FULL-TEXT
ARTICLE
Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past,
Present, and Future.
Harris M, Nosyk B, Harrigan R, et al
AIDS
Res Treat.
2012;2012:595762.
Paper
Cost-effectiveness analysis of first-line HAART.
Maggiolo F, Di Matteo S, Masini G,
et al
J Int AIDS Soc. 2012 Nov 11;
Abstract
Cost-efficacy of European AIDS Clinical Society-recommended initial
antiretroviral regimens for treatment of HIV infection in Portugal.
Aldir I, Doroana M, Oliveira J,
et al
J Int AIDS Soc. 2012 Nov
11;15(6):18374.
Abstract
A MultiFactorial Risk Score to weigh toxicities and
co-morbidities relative to costs of antiretrovirals in a cohort of HIV-infected
patients.
Tontodonati M, Sozio F, Vadini F, et al
J Int AIDS Soc. 2012 Nov
11;15(6):18387.
Abstract
Cost-effectiveness evaluation of initial HAART regimens for
managing HIV-infected patients according to real clinical practice.
Castagna A, Colombo G, Salpietro S,
et al
J Int AIDS Soc. 2012 Nov
11;15(6):18386.
Abstract
Cost-Effectiveness of Antiretroviral Therapy for
Multidrug-Resistant HIV: Past, Present, and Future.
Harris M, Nosyk B, Harrigan R, et al
AIDS Res Treat. 2012;2012:595762
Abstract
FULL-TEXT ARTICLE
The Determinants of HIV Treatment Costs in Resource Limited Settings.
Menzies NA, Berruti AA, Blandford JM.
PLoS One.
2012;7(11):e48726.
Paper |
Internet
Documents
Home PageHAART
Main Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader